Technology
Health
Pharmaceutical

MediWound

$5.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.57%) Today
-$0.03 (-0.57%) Today

Why Robinhood?

You can buy or sell MediWound and other stocks, options, ETFs, and crypto commission-free!

About

MediWound Ltd. Ordinary Shares, also called MediWound, is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of novel products to address needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders. Read More Its medicinal product, NexoBrid, is used to remove eschar in adults patients with deep partial- and full-thickness thermal burns. The company was founded by Lior Rosenberg and Marian Gorecki on January 27, 2000 and is headquartered in Yavne, Israel.

Employees
76
Headquarters
Yavne, HaMerkaz
Founded
2000
Market Cap
141.87M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
112.94K
High Today
$5.24
Low Today
$5.01
Open Price
$5.01
Volume
12.82K
52 Week High
$7.35
52 Week Low
$3.76

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
Asia (Non-China)
Asia

News

StreetInsiderMar 12

MediWound (MDWD) CEO Change, Fact Pattern Suggests a Deal May Be Near - SunTrust

(Updated - March 12, 2019 11:06 AM EDT) (updated to expand on analyst comments) SunTrust Robinson Humphrey analyst Bruce Nudell said the CEO change at MediWound (NASDAQ: MDWD), announced this morning, and other facts, could suggest a deal is near. Nudell said, after speaking with management, the move by Gal Cohen to step down after 12 years as CEO was a personal decision to pursue new opportunities. Current Chairman, Stephen Wills, will serve as Active Chairman and will continue to head the ongoing strat...

55
Seeking AlphaMar 12

MediWound announces leadership changes

MediWound's (NASDAQ:MDWD) CEO, Gal Cohen, has decided to step down from his position. He will end his term by the end of May. Sharon Malka, CFO and COO, will be appointed as CEO, and Stephen T. Wills, Chairman of the Board of Directors, will serve as Active Chairman. Prior to joining MediWound, Mr. Malka held various senior finance roles, including, as a co-founder and partner at Variance Economic Consulting, a full-service financial consulting firm, and as a senior manager at the Israeli member firm of P...

2
Yahoo FinanceMar 11

Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline

Wall Street expects a year-over-year decline in earnings on higher revenues when MediWound (MDWD) reports results for the quarter ended December 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

16

Earnings

-$0.20
-$0.16
-$0.12
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.15 per share
Actual
Available Mar 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.